Table:
Design of clinical trials using recombinant canarypox and protein immunogens
| Prime | Protein boost | Adjuvant | Location | Description | Participants | Efficacy | |
|---|---|---|---|---|---|---|---|
| RV1447 PAE/B/alum | Recombinant canarypox (ALVAC; vCP1521) containing HIV-1 gag (clade B LAI), pro (clade B LAI), env (gp120 AE 92TH023), and gp41 (clade B LAI) transmembrane anchor | AIDSVAX (gp120* clade B, strain MN, with gD tag and gp120* clade AE, strain A244, with gD tag) | Alum | Thailand | Phase 2b/3; efficacy; double-blind, placebo-controlled (n=16 402) | HIV uninfected adults 18–30 years of age, regardless of HIV risk | 31·2% (p=0·04) |
| HVTN 0978 PAE/B/alum | Recombinant canarypox (ALVAC-vCP1521) containing HIV-1 gag (clade B LAI), pro (clade B LAI), env (gp120 AE 92TH023), and gp41 (clade B LAI) transmembrane anchor | AIDSVAX (gp120* clade B, strain MN, with gD tag and gp120* clade AE, strain A244, with gD tag) | Alum | South Africa | Phase 1b; immunogenicity; double-blind, placebo-controlled (n=100) | HIV uninfected adults 18–35 years of age | NA |
| HVTN 1009 Pc/MF59 | Recombinant canarypox (ALVAC-vCP2438) containing HIV-1 gag (clade B LAI), pro (clade B LAI), env (gp120; clade ZM96.C), and gp41 (clade B LAI) transmembrane anchor | gp120* clade C, strain TV1, and gp120* clade C, strain 1086 (no gD tag) | MF59 | South Africa | Phase 1/2; immunogenicity; double-blind, placebo-controlled (n=252) | HIV uninfected adults 18–40 years of age at low risk of acquiring HIV | NA |
| HVTN 7021 Pc/MF59 | Recombinant canarypox (ALVAC-vCP2438) containing HIV-1 gag (clade B LAI), pro (clade B LAI), env (gp120; clade ZM96.C), and gp41 (clade B LAI) transmembrane anchor | gp120* clade C, strain TV1, and gp120* clade C, strain 1086 (no gD tag) | MF59 | South Africa | Phase 2b/3; efficacy; double-blind, placebo-controlled (n=5404) | HIV uninfected adults 18–35 years of age who are sexually active | None |
*
With N-terminal 11 amino acid deletion. NA=not applicable.